We are live on ! Find out more
KRBP

Kiromic BioPharma, Inc. Common Stock
KRBP

Delisted

KRBP was delisted on the 13th of September, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Kiromic BioPharma, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 5 → 0 (-5)

100% less capital invested

Capital invested by funds: $6.13K → $0 (-$6.13K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
–
Holders Change
-5
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$3.81K
2
BlackRock
BlackRock
New York
-$2.2K
3
Morgan Stanley
Morgan Stanley
New York
-$109
4
Wells Fargo
Wells Fargo
California
-$16
5
Group One Trading
Group One Trading
Illinois
-$3
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
1
Tower Research Capital (TRC)
New York
– -$3.81K -1,399 Closed
BlackRock
2
BlackRock
New York
– -$2.2K -809 Closed
Morgan Stanley
3
Morgan Stanley
New York
– -$109 -40 Closed
Wells Fargo
4
Wells Fargo
California
– -$16 -6 Closed
Group One Trading
5
Group One Trading
Illinois
– -$3 -1 Closed

KRBP Hedge Fund Activity: Q3 2023 in Review

0 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q3 2023, worth a combined $0 — down 100% from $6.13K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of KRBP and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $3.81K sold.

  • 0 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q3 2023, down from 5 in Q2 2023.
  • Funds reported $0 of Kiromic BioPharma, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q3 2023 and 5 closed out, a net change of -5 holders.
  • The largest Kiromic BioPharma, Inc. Common Stock seller in Q3 2023 was Tower Research Capital (TRC), an estimated $3.81K sold.

Based on aggregated 13F filings for Q3 2023.